| Prev Close | 18.27 |
| Open | 18.14 |
| Day Low/High | 17.84 / 18.47 |
| 52 Wk Low/High | 7.26 / 26.59 |
| Volume | 852.23K |
| Avg Volume | 1.32M |
Iovance Biotherapeutics Inc. (IOVA)
17.95
0.32
1.75
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 123.83M |
| Market Cap | 2.25B |
| EPS | -1.30 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
2 Promising Biotech Stocks That Insiders Are Snapping Up
Shares of Iovance Biotherapeutics and Reata Pharmaceuticals took it on the chin in the fourth quarter, but both companies seem ready to reward shareholders for their patience.
Here's a Handful of Small Biotechs Where Insiders Are Buying
Quotient Limited, Iovance Biotherapeutics and AVEO Pharmaceuticals are among the names seeing insider purchases.
A Lesson to Learn From Thursday's Market Action
You don't have to be Sigmund Freud to understand the psychology here.
Small-Cap Stocks Lead the Way
As interest rate fears ease slightly, indexes rebound.
4 Small Speculative Names on My Radar
While I'm waiting for some index excitement I'm focused on trades in individual stocks.
Lennar Is One of 6 Stocks Poised to Change Direction
These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.
Sound Familiar? Dovish Fed Talk Induces Stock Reversal
The market's reaction to James Bullard's comments this morning is following an all-too-common pattern.
Biotech Heats Up as Fear of Missing Out Returns
It's hard to believe the bounce will continue to run in V-shaped fashion.
Focused on Two Sectors
If we have a little consolidating action here the buyers will start pushing again.
Markets Face Heavy News Flow in Next 48 Hours
In addition to the State of the Union address and the Fed interest rate decision, companies representing about 25% of the Nasdaq 100's market cap will report results in the next two days.
'Normal' Market Selloff Feels Much Worse Than It Really Is
While painful to longs, the market will be better for it.
This Market Badly Needs a Rest
It would be a longer-term positive if the overbought conditions are alleviated.
Building in Biotech, Adding to Twitter
The challenge of this market is to keep finding new buy entries as more and more stocks become extended.
Market Gets a Little Bumpy, but Stock-Picking Still Rocks
Only when the picking worsens will I start to worry.
Biotech Looks Good and I'm Buying
The sector has been a great trading group lately and I bought these 2 names this morning.
In This Booming Stock Market, Think Like a Programmer Not a Critic
What drives the trading action are structural issues, not macroeconomic news events or political drama.
The Stock Market Is Facing One Big Obstacle Right Now
You have to wonder how much longer we can run without a pullback of at least 2%.